Impact of nocturnal home hemodialysis on anemia management in patients with end-stage renal disease

Clinical Nephrology

Volumn 63, Issue 3, 2005, Pages 202-208

  Schwartz, D I ^a   Pierratos, A ^b   Richardson, R M A ^a   Fenton, S S A ^a   Chan, Christopher T ^a,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NONE   (Canada)

Author keywords

Anemia; Daily hemodialysis; Erythropoietin; Home hemodialysis; Nocturnal hemodialysis

Indexed keywords

FERRITIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; HOME DIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SELF CARE;

EID: 14944384224     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP63202     Document Type: Article

References (45)

1. Barany P 2001 Inflammation, serum C-reactive protein, and erythropoietin resistance. Nephrol Dial Transplant 16: 224-227
2. Brissenden JE, Pierratos A, Ouwendyk M et al 1998 Improvements in quality of life with nocturnal hemodialysis. J Am Soc Nephrol 9: 168A
3. Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW 1990 Hypertension following erythropoietin therapy in anemic hemodialysis patient. Am J Hypertens 3: 947-955
4. Buemi M, Allegra A, Lagana A, Aloisi C, Privitera M, Morabito N, Frisina N 1993 Effects of the evening i.v. administration of erythropoietin in haemodialyzed patients. Rev Eur Sci Med Pharmacol 15: 195-197
5. Buoncristiani U, Quintaliani G, Cozzari M, Giombini LRM 1988 Daily dialysis: long-term clinical and metabolic results. Kidney Int 24: S137-S140
6. Buoncristiani U 1998 Fifteen years of clinical experience with daily hemodialysis. Nephrol Dial Transplant 13 (Sappl 6): 148-151
7. Casati S, Passerini P, Campise MR, Graziani G, Cesana B, Perisic M, Ponticelli C 1987 Benefits and risks of protracted treatment with recombinant erythropoietin in patients having haemodialysis. BMJ 295: 1017-1020
8. Chan C, Floras J, Miller J, Richardson RM, Pierratos A 2002a Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 61: 2235-2239
9. Chan C, Floras J, Miller J, Pierratos A 2002b Improvement in ejection fraction by nocturnal hemodialysis in end-stage renal failure patients with coexisting heart failure. Nephrol Dial Transplant 17: 1518-1521
10. Charra B, Calemard E, Ruffet M, Chazot C, Terrat JC, Vanel T, Laurent G 1992 Survival as an index of adequacy of dialysis. Kidney Int 41: 1286-1291
11. Delano BG 1989 Improvements in quality of life following treatment with rHuEPO in anemic hemodialysis patients. Am J Kidney Dis 14 (2 Suppl 1): 14-18
12. Evans RW, Rader B, Manninen DL 1990 The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 263: 825-830
13. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE 1996 The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28: 53-61
14. Foley RN, Parfrey PS, Morgan J et al 2000 Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58: 1325-1335
15. Galli F, Beninati S, Benedetti S, Lentini A, Canestrari F, Tabilio A, Buoncristiani U 2001 Polymeric protein-polyamine conjugates: a new class of uremic toxins affecting erythropoiesis. Kidney Int 59 (Suppl 78): S73-S76
16. Galluci MT, Lubrano R, Meloni C, Marosetti M, Manca di Villahermosa S, Scoppi P, Palombo G, Castello MA, Casciani CU 1999 Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients. Clin Nephrol 52: 239-245
17. Gunnell J, Yeun JY, Depner TA, Kaysen GA 1999 Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis 33: 63-72
18. Hanly PJ, Pierratos A 2001 Improvement of sleep apnea in patients with chronic renal failure who undergo nocturnal hemodialysis. N Engl J Med 344: 102-107
19. Ifudu, O, Feldman J, Friedman EA 1996 The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med 224: 420-425
20. Kimmel P, Greer J, Milam R, Thamer M 2000 Trends in erythropoietin therapy in the U.S. dialysis population: 1995 - 1998. Semin Nephrol 20: 335-344
21. Klarenbach S, Heidenheim AP, Leitch R, Lindsay RM 2002 Reduced requirement for erythropoietin with quotidian hemodialysis therapy. ASAIO J 48: 57-61
22. Kooistra M, Vos J, Koomans H, Vos PF 1998 Daily home haemodialysis in The Netherlands: effects on metabolic control, haemodynamics, and quality of life. Nephrol Dial Transplant 13: 2853-2860
23. London GM, Zins B, Pannier B, Naret C, Berthelot JM, Jacquot C, Safar M, Drueke TB 1989 Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 36: 878-882
24. Ly JPH, Marticorena RM, Donnelly SM 2002 Red blood cell survival in chronic renal failure. J Am Soc Nephrol 13: 261A
25. Ma JZ, Ebben J, Xia H, Collins AJ 1999 Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10: 610-619
26. Macdougall IC 2001 Role of uremic toxins in exacerbating anemia in renal failure. Kidney Int 59 (Suppl 78): S67-S72
27. Mastrangelo F, Alfonso M, Napoli V, DeBlasi V, Russo F, Patruno P 1998 Dialysis with increased frequency of sessions (Lecce dialysis). Nephrol Dial Transplant 13 (Suppl 6): S139-S147
28. McClellan WM, Frankenfield, Johnson CA et al 2000 ESRD Core Indicators Working Group. Hematocrit and erythropoietin dose are associated with dose of dialysis among adult hemodialysis patients: results from the 1998 ESRD Core Indicators Project. J Am Soc Nephrol 11: 287A
29. Mocks J, Franke W, Ehmer B et al 1997 Analysis of safety database for long-term epoetin-beta treatment. A meta-analysis covering 3697 patients. In: Koch KM, Stein G (eds) Pathogenetic and Therapeutic Aspects of Chronic Renal Failure 1997. Marcel Dekker, New York, pp 163-179
30. Mohr PE, Neumann PJ, Franco SJ, Marainen J, Lockridge R, Ting G 2001 The case for daily dialysis: its impact on costs and quality of life. Am J Kidney Dis 37: 777-789
31. Movilli, E 2001 Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in hemodialysis patients. Nephrol Dial Transplant 16: 111-114
32. Mucsi I, Hercz G, Uldall R, Ouwendyk M, Francoeur R, Pierratos A 1998 Control of serum phosphate without any phosphate binders in patients treated with nocturnal hemodialysis. Kidney Int 53: 1399-1404
33. NKF-K/DOQI 2001 Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 37 (1 Suppl 1): S182-238
34. Pierratos A 1999 Nocturnal home haemodialysis: an update on a 5-year experience. Nephrol Dial Transplant 14: 2835-2840
35. Retting RA 2001 If daily dialysis is the answer, what is the question? Am J Kidney Dis 37: 862-865
36. 2-Microglobulin kinetics in nocturnal hemodialysis. Nephrol Dial Transplant 15: 58-64
37. Rao M, Muirhead N, Klarenbach S, Moist L, Lindsay RM 2003 Management of anemia with quotidian hemodialysis. Am J Kidney Dis 42 (1 Suppl 1): 18-23
38. Ritz E, Zeier M, Schneider P, Jones E 1994 Cardiovascular mortality of patients with polycystic kidney disease on dialysis: is there a lesson to learn? Nephron 66: 125-128
39. Sasaki N, Ando Y, Kusano E, Asano Y 2003 A case of erythropoietin-induced hypertension in a bilaterally nephrectomized patient. ASAIO J 49: 131-135
40. Silverberg DS, Wexler D, Blum M et al 2000 The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35: 1737-1744
41. Ting G, Zarghamee S, Carrie B et al 1998 Short daily hemodialysis - clinical outcomes and quality of life. J Am Soc Nephrol 9: 228A
42. Tisher C, Bastl C, Bistrian B et al 1994 Consensus Development Conference Panel: Morbidity and mortality of renal dialysis: An NIH consensus conference statement. Ann Intern Med 121: 62-70
43. Wallner SF, Kurnick JE, Ward HP, Vautrin R, Alfrey AC 1976 The anemia of chronic renal failure and chronic diseases: in vitro studies of erythropoiesis. Blood 47: 561-569
44. Wallner SF, Vautrin RM, Kurnick JE, Ward HP 1978 The effect of serum from patients with chronic renal failure on erythroid colony growth in vitro. J Lab Clin Med 92: 370-375
45. Woods J, Port F, Orzol S Buoncristiani U, Young E, Wolfe RA, Held PJ 1999 Clinical and biochemical correlates of starting "daily" hemodialysis. Kidney Int 55: 2467-2476